{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:30:28Z","timestamp":1770139828542,"version":"3.49.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"1-2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1080\/17512433.2024.2447775","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T12:42:41Z","timestamp":1736340161000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Closing the gaps in the access to quality-assured medicines for global health: The case for oxytocin for postpartum haemorrhage"],"prefix":"10.1080","volume":"18","author":[{"given":"CC","family":"Lee","sequence":"first","affiliation":[{"name":"Johnson & Johnson","place":["High Wycombe, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luther","family":"Gwaza","sequence":"additional","affiliation":[{"name":"World Health Organization","place":["Geneva, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Rombouts","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Beerse, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hu","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Raritan, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutendo","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Regulation and Prequalification Department, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Remmerie","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Beerse, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chioma","family":"Ejekam","sequence":"additional","affiliation":[{"name":"Advanced Center of Excellence for Drug Research, University of Lagos, Lagos, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehinde","family":"Okunade","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pete","family":"Lambert","sequence":"additional","affiliation":[{"name":"Monash University","place":["Parkville, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"e_1_3_7_3_1","unstructured":"World Health Assembly. Availability safety and quality of blood products (WHA63.12). Geneva: World Health Organization; 2010 [cited 2024 Dec 12]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/3086\/A63_R12-en.pdf?sequence=1"},{"key":"e_1_3_7_4_1","unstructured":"World Health Assembly. Regulatory system strengthening for medical products (WHA67.20). Geneva: World Health Organization; 2014 [cited 2024 Dec 12]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/162864\/A67_R20-en.pdf?sequence=1"},{"key":"e_1_3_7_5_1","unstructured":"World Health Assembly. Access to biotherapeutic products including similar biotherapeutic products1 and ensuring their quality safety and efficacy (WHA67.21). Geneva: World Health Organization; 2014 [cited 2024 Dec 12]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/162867\/A67_R21-en.pdf"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00457"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1057\/jphp.2016.8"},{"key":"e_1_3_7_8_1","unstructured":"ICH. Articles of Association. Geneva: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2020 [cited 2024 Apr 19]. Available from: https:\/\/admin.ich.org\/sites\/default\/files\/inline-files\/ArticlesOfAssociation_Approved_v5-0_2020_1118.pdf"},{"key":"e_1_3_7_9_1","unstructured":"World Health Organization. Basic documents. Geneva: World Health Organization; 2020 [cited 2024 Dec 12]. Available from: https:\/\/iris.who.int\/handle\/10665\/339554"},{"key":"e_1_3_7_10_1","volume-title":"WHO handbook for guideline development","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. WHO handbook for guideline development. 2nd ed. Geneva, Switzerland: World Health Organization; 2014.","edition":"2"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-683"},{"key":"e_1_3_7_12_1","unstructured":"World Health Organization. List of WHO-Listed authorities (WLA). Geneva: World Health Organization; 2024 [cited 2024 Dec 13]. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/regulatory-systems\/wla\/list_of_wla_may24.pdf?sfvrsn=1f6c2140_37&download=true"},{"key":"e_1_3_7_13_1","unstructured":"World Health Organization. List of transitional WLAs. Geneva: World Health Organization; 2024 [cited 2024 Dec 13]. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/regulatory-systems\/wla\/list-of-transitional-wlas.pdf?sfvrsn=a3011e1e_16&download=true"},{"key":"e_1_3_7_14_1","unstructured":"World Health Organization. List of national regulatory authorities (NRAs) operating at maturity level 3 (ML3) and maturity level 4 (ML4). Geneva: World Health Organization; 2024 [cited 2024 Dec 13]. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/regulatory-systems\/wla\/list-of-nras-operating-at-ml3-and-ml4.pdf?sfvrsn=ee93064f_19&download=true"},{"key":"e_1_3_7_15_1","unstructured":"World Health Organization. Global Benchmarking Tool (GBT) for evaluation of national regulatory systems of medical products revision VI. Geneva: World Health Organization; 2021 [cited 2024 Dec 13]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/341243\/9789240020245-eng.pdf?sequence=1"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1724782"},{"key":"e_1_3_7_17_1","unstructured":"Swissmedic. Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products (MAGHP). Bern: Swiss Agency for Therapeutic Products; 2023 [cited 2024 Dec 13]. Available from: https:\/\/www.swissmedic.ch\/dam\/swissmedic\/en\/dokumente\/stab\/networking\/maghp_procedure.pdf.download.pdf\/maghp_procedure.pdf"},{"key":"e_1_3_7_18_1","unstructured":"WHO Expert Committee on Specifications for Pharmaceutical Preparations. Annex 11: Collaborative procedure in the assessment and accelerated national registration of pharmaceutical products and vaccines approved by stringent regulatory authorities. In. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-second report. WHO Technical Report Series No 1010. Geneva Switzerland: World Health Organization; 2018. p. 353\u2013406."},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2037419"},{"key":"e_1_3_7_20_1","unstructured":"World Health Organization. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Geneva. 2018 [cited 2024 Dec 13]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241550420"},{"key":"e_1_3_7_21_1","unstructured":"Jhpiego. Business case: Investing in production of high-quality oxytocin for low-resource settings. Baltimore (MD): Jhpiego; 2014 [cited 2024 Dec 13]. Available from: https:\/\/www.conceptfoundation.org\/wp-content\/uploads\/2015\/06\/BusinessCase_Oxytocin_web.pdf"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.13998"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-020-00205-7"},{"key":"e_1_3_7_24_1","unstructured":"World Health Organization. Assessment of shelf life and storage conditions of registered oxytocin in Southern African Development Community (SADC). Geneva: World Health Organization; 2021 [cited 2024 Feb 6]. Available from: https:\/\/www.tmda.go.tz\/uploads\/files\/Assessment%20of%20oxytocin%20in%20SADC%20Report_FinalDraft_6July2021%20(1).pdf"},{"key":"e_1_3_7_25_1","unstructured":"ICH. Q1A(R2): Stability testing of new drug substances and products. Geneva: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 2003 [cited 2024 Feb 5]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q1A%28R2%29%20Guideline.pdf"},{"key":"e_1_3_7_26_1","unstructured":"WHO Expert Committee on Specifications for Pharmaceutical Preparations. Annex 10: Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. In. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-second report. WHO Technical Report Series No. 1010. Geneva Switzerland: World Health Organization; 2018. p. 309\u2013351."},{"key":"e_1_3_7_27_1","unstructured":"World Health Organization. Stability conditions for WHO Member States by region. Geneva: World Health Organization; 2021 [cited 2024 Jun 17]. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/norms-and-standards\/guidelines\/regulatory-standards\/trs953-annex2-appendix1-stability-conditions-table-2018.pdf?sfvrsn=74032aec_12&download=true"},{"key":"e_1_3_7_28_1","unstructured":"World Health Organization. WHO\/UNICEF\/UNFPA Joint Statement: Appropriate Storage and Management of Oxytocin \u2013 A Key Commodity for Maternal Health. Geneva: World Health Organization; 2019 [cited 2024 Jan 17]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/311524"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258096"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208367"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062801"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000431"},{"key":"e_1_3_7_33_1","unstructured":"World Health Organization. WHO PQT-Medicine guidance document: Oxytocin injection- Clarification of stability data and storage statement requirements. Geneva: World Health Organization; 2018 [cited 2024 Dec 13]. Available from: https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/document_files\/150%20stability%20data%20Oxytocin%20Oct2018.pdf"},{"key":"e_1_3_7_34_1","first-page":"205","volume-title":"World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-fifth report. WHO Technical Report Series, No. 1033","author":"WHO Expert Committee on Specifications for Pharmaceutical Preparations","year":"2021","unstructured":"WHO Expert Committee on Specifications for Pharmaceutical Preparations. Annex 9: Guidelines on the implementation of the WHO Certification scheme on the quality of pharmaceutical products moving in international commerce. In: World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fifty-fifth report. WHO Technical Report Series, No. 1033. Geneva, Switzerland: World Health Organization; 2021. p. 205\u2013235."},{"key":"e_1_3_7_35_1","unstructured":"Human Medicines: Register of electronic export certificates [internet]. Department of Health and Social care and MHRA. 2024 [cited 2024 Dec 7]. Available from: https:\/\/www.gov.uk\/government\/publications\/human-medicines-register-of-electronic-export-certificates"},{"key":"e_1_3_7_36_1","unstructured":"Products website for Medicine Information (Oxytocin) [Internet]. Medicines and Healthcare products Regulatory Agency. 2024 [cited 2024 Dec 7]. Available from: https:\/\/products.mhra.gov.uk\/substance\/?substance=OXYTOCIN"},{"key":"e_1_3_7_37_1","unstructured":"WHO Expert Committee on Specifications for Pharmaceutical Preparations. Annex 4: Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product for the WHO prequalification of medicines programme: Quality part. In. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Forty-sixth report. WHO Technical Report Series No. 970. Geneva Switzerland: World Health Organization; 2012. p. 751\u2013820."},{"key":"e_1_3_7_38_1","unstructured":"WHO Expert Committee on Specifications for Pharmaceutical Preparations. Annex 8: Collaborative procedure between the World Health Organization (WHO) Prequalification Team and National Regulatory Authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines. In. WHO Expert Committee on Specifications for Pharmaceutical Preparations: Fiftieth report. WHO Technical Report Series No. 996. Geneva Switzerland: World Health Organization; 2016. p. 263\u2013304."},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.14200"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16135"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.07.020"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-013109"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.14305"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805489"},{"key":"e_1_3_7_45_1","unstructured":"World Health Organization. WHO Coordinated Scientific Advice Procedure for health product research and development. Geneva: World Health Organization; 2021 [cited 2024 Dec 13]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/342560\/9789240031043-eng.pdf"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2024.2447775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T08:48:42Z","timestamp":1739782122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2024.2447775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":43,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1080\/17512433.2024.2447775"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2024.2447775","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}